DelMar Pharmaceuticals Inc (NASDAQ:DMPI) gapped up prior to trading on Friday . The stock had previously closed at $0.80, but opened at $0.82. DelMar Pharmaceuticals shares last traded at $1.05, with a volume of 3,075,900 shares.
A number of brokerages have weighed in on DMPI. Maxim Group reaffirmed a “buy” rating on shares of DelMar Pharmaceuticals in a research note on Friday, November 15th. Zacks Investment Research raised shares of DelMar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 29th.
The firm has a market capitalization of $1.82 million, a P/E ratio of -0.33 and a beta of 1.30. The stock’s 50 day moving average is $0.60 and its two-hundred day moving average is $1.21.
DelMar Pharmaceuticals (NASDAQ:DMPI) last posted its quarterly earnings results on Tuesday, September 10th. The company reported ($0.89) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.59). Equities research analysts anticipate that DelMar Pharmaceuticals Inc will post -1.2 earnings per share for the current fiscal year.
DelMar Pharmaceuticals Company Profile (NASDAQ:DMPI)
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.
Featured Story: The risks of owning bonds
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.